RESUMO
Systemic lupus erythematosus (SLE)is a multisystem autoimmune disease, characterized by clinical heterogeneity, ranging from mild to severe, life-threatening manifestations. Although gastrointestinal (GI) symptoms are frequently encountered during disease course (mainly associated with complications of medication or infection), primary GI involvement due to SLE is rare. Among variable presentations, lupus abdominal serositis (defined as peritonitis if accompanied by symptoms and signs of acute abdomen) and lupus enteritis/mesenteric vasculitis are causes of SLE-related acute abdominal pain. They occur, although not always, in the context of high disease activity and prompt diagnosis and treatment is necessary due to their potential severe complications. However, the diagnosis of these manifestations remains challenging even for experts, especially in cases of "organ-dominant" lupus flares. Exclusion of these rare manifestations from classification criteria increases the likelihood of misdiagnosis and highlights the inherent limitations of classification criteria when the latter are used for diagnosis. Urgent abdominal computed tomography can lead to a prompt diagnosis of these lupus manifestations, especially characteristic for lupus mesenteric vasculitis. Herein, we describe four cases of patients with lupus flare, presenting with acute abdominal manifestations and highlight the potential complexity of diagnostic approach in such situations.
RESUMO
OBJECTIVE: Tumor necrosis factor-a (TNF-a) is a key cytokine in the pathogenesis of chronic inflammatory arthritides, has proatherogenic effects, and may be positively correlated with impairment of the action of insulin. Patients with chronic inflammatory arthritides have an increased risk for cardiovascular diseases. We assessed whether anti-TNF-a treatment modifies the unfavorable lipid profile induced by chronic inflammatory arthritides. METHODS: Sixty patients (24 with rheumatoid arthritis, 26 ankylosing spondylitis, and 10 psoriatic arthritis) receiving infliximab because of ongoing disease activity despite disease modifying drugs (DMARD) were prospectively studied for 6 months. Lipid profile, total cholesterol/high density lipoprotein cholesterol (TC/HDL-C), and low density lipoprotein cholesterol (LDL-C)/HDL-C ratios, as well as disease activity indices (DAS28 and BASDAI), were assessed. RESULTS: A sustained increase of serum HDL-C was observed [mean increase (95% CI)] 5 (3-7) mg/dl, 3.5 (1-6) mg/dl, and 3 (1-5) mg/dl at 1, 3, and 6 months, respectively (p < 0.01). Compared to nonresponders, HDL-C increased significantly more in EULAR or BASDAI responders (0.8 vs 5.8 mg/dl; p = 0.05). Serum TC was significantly increased [11 (4-8) mg/dl; p = 0.001] only after the first month of treatment. TC/HDL-C and LDL-C/HDL-C decreased only after the first month [0.3 (0.1-0.4), p < 0.01, and 0.2 (0.1-0.4), p < 0.01, respectively]. For patients with baseline LDL-C > 130 mg/dl, LDL-C/HDL-C decreased (p < 0.05) during the whole study period and TC/HDL-C decreased (p < 0.05) at 1 and 3 months. CONCLUSION: Anti-TNF-a treatment in patients with chronic inflammatory arthritides induces a modest, but sustained, increase in serum HDL-C levels, which may have a favorable effect in reducing the cardiovascular risk in these patients.
